The well-being of humankind is dependent upon advances in biological and clinical sciences. For many diseases, an early diagnosis and objective measures of outcomes are essential for reducing mortality and morbidity. Part of this package entails the appropriate use of biomarkers. These are biological indicators which often are used routinely in the clinical setting. Recent advances in the chemical and physical sciences have enabled new biomarkers to be developed. This does not mean that traditional markers are redundant as detailed investigations have identified both limitations and advantages in their usage as well as new applications. This book General Methods in Biomarker Research and their Applications combines both traditional, new and emerging biomarkers in a single publication. The chapters contained in this book have wide applicability to many diseases.
Inhoudsopgave
Biomarker for Amyotrophic Lateral Sclerosis (Motor Neurone Disease).- Biomarkers and their applications to toxicology and toxicogenomics.- Biomarkers for Depression.- Biomarkers in Chronic Obstructive Pulmonary Disease (COPD): Current Concerns and Future Prospects.- Biomarkers in Urine and Use of Creatinine.- Biomarkers of Graft-Versus-Host Disease.- Biomarkers of Menopause.- Biomarkers of Parkinson’s Disease.- Biomarkers of Vector Bites.- Biomarkers of the menopause.- Chronic Heart Failure and Serum Collagen.- FABP3 as biomarkers.- Fetal Membrane Biomarkers.- Flow Cytometry as Platform for Biomarker Evaluation.- Formalin-fixed paraffin-embedded tissue (FFPET) sections for biomarker discovery.- Glycomics as biomarkers.- Inflammasome Proteins as Biomarkers of Injury and Disease.- Isoprostanes as biomarkers of disease and early biological effect.-Mass spectrometry for biomarker discovery.- Micro RNA as Biomarker for Brain Injury.- MIP-1alpha as biomarker.- Natriuretic Peptides for Diagnosis, Prognosis and Management of Heart Failure.- OMICS-based approaches to biomarker discovery and challenges of subsequent validation.- Pediatric biomarkers after cardac surgery.- Pentraxin 3 as Biomarker.- pfetin: Novel prognostic biomarker.- Plasma galectin-3 as biomarker.- S100B as a Biomarker.- Salivary amylase as a stress biomarker.- Seasonal allergic rhinitis and systems biology-oriented biomarker discovery.- Serum Heat Shock Proteins as Novel Biomarker for Heart Failure.- Urinary Biomarkers of Environmental Health: Jet Fuel.- YKL-40 as Biomarker: Focus on Cardiovascular Disease.
Over de auteur
Professor Victor R. Preedy is a senior faculty member of King’s College London (Professor of Nutritional Biochemistry) and King’s College Hospital (Professor of Clinical Biochemistry). He is attached to both the Diabetes and Nutritional Sciences Division and the Department of Nutrition and Dietetics. He is also Director of the Genomics Centre and a member of the School of Medicine. Professor Preedy graduated in 1974 with an Honours Degree in Biology and Physiology with Pharmacology. He gained his University of London Ph D in 1981. In 1993 he gained his second doctoral degree, for his outstanding contribution to protein metabolism in health and disease. He has received membership and fellowship of a number of academic and professional bodies in the UK, including the Royal College of Pathologists, the Royal Institute of Public Health, and the Royal Society of Chemistry. Professor Preedy has published over 570 articles, which includes 165 peer-reviewed manuscripts based on original research, 100 reviews and over 50 books and book volumes.